1436851-35-2

Upstream product

• 554-84-7 meta-nitrophenol 
• 76661-24-0 2,5-dichloro-4-(3-nitrophenoxy)pyrimidine 
• 1374641-74-3 3-((2,5-dichloropyrimidin-4-yl)oxy)aniline 
• 1374641-75-4 N-(3-((2,5-dichloropyrimidin-4-yl)oxy)phenyl)acrylamide 
• 1436851-28-3 C₂₈H₃₁ClN₆O₅ 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 1436851-29-4 2-(4-(4-((4-(3-acrylamidophenoxy)-5-chloropyrimidin-2-yl)-amino)-3-methoxyphenyl)piperazin-1-yl)acetic acid 
• 1436851-30-7 4-((1-aminopropan-2-yl)oxy)-3-(benzenesulfonyl)-1,2,5-oxadiazole-2-oxide 
• 1436851-26-1 ethyl 2-(4-(3-methoxy-4-nitrophenyl)piperazin-1-yl)acetate 
• 1436851-27-2 ethyl 2-[4-(4-amino-3-methoxyphenyl)piperazin-1-yl]acetate 

Relevant academic research and scientific papers

Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer

A series of hybrids (12a-k) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of non-small-cell lung cancer (NSCLC). Compound 12k exhibited